HCV Antivirals Associated With Reduced Risk of CVD Events HCV Antivirals Associated With Reduced Risk of CVD Events
Hepatitis C virus infection has been associated with a greater risk of cardiovascular disease. Might antiviral therapy reduce the risk?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 9, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Homelessness, unstable housing, and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
Review (55 studies) found recent homelessness or unstable housing linked to increased risk of acquiring HIV (crude relative risk 1.55; 95% CI 1.23 –1.95; p=0.0002) and hepatitis C (1.65; 1.44–1.90; p (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 9, 2021 Category: Consumer Health News Source Type: news

Cadila seeks nod to repurpose Hepatitis C drug for COVID-19 in India
India's Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drugmaker said on Monday. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 5, 2021 Category: Pharmaceuticals Source Type: news

ART Likely Less Effective in Women With HIV Versus Other Chronic Viral Illnesses ART Likely Less Effective in Women With HIV Versus Other Chronic Viral Illnesses
HIV-infected women who underwent assisted reproductive technology (ART) had a lower live birth rate than those with chronic hepatitis B or hepatitis C virus in a cohort study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 1, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Chronic viral infections can have lasting effects on human immunity, similar to aging
(Buck Institute for Research on Aging) Research suggests that chronic viral infections have a profound and lasting impact on the immune system in ways that are similar to those seen during aging. Using systems immunology and artificial intelligence, researchers profiled and compared immune responses in a cohort of aging individuals, people with HIV on anti-retroviral therapy, and people infected with hepatitis C before and after the virus was treated with a drug that has up to a 97% cure rate. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 29, 2021 Category: Infectious Diseases Source Type: news

Homelessness and unstable housing are associated with increased HIV and HCV risk among people who inject drugs
Homelessness and unstable housing are associated with a substantial increase in HIV and hepatitis C virus (HCV) acquisition risk among people who inject drugs, according to research led by the NIHR Health Protection Research Unit in Behavioural Science and Evaluation at the University of Bristol. (Source: University of Bristol news)
Source: University of Bristol news - March 26, 2021 Category: Universities & Medical Training Tags: Health, Research; Faculty of Health Sciences, Bristol Medical School, Faculty of Health Sciences; Press Release Source Type: news

Babies are being born with congenital syphilis in Sask. This is a public health emergency
We are about to see a third pandemic. Few are thinking about it, but it's keeping me up at night. This is a monster with three heads: HIV, syphilis and hepatitis C.   (Source: CBC | Health)
Source: CBC | Health - March 26, 2021 Category: Consumer Health News Tags: News/Canada/Saskatchewan Source Type: news

In trying to contain COVID-19, we could be missing spread of HIV, hepatitis C and syphilis, experts warn
Public health experts say the COVID-19 pandemic has overshadowed other epidemics that need attention. Testing for HIV and hepatitis C has plummeted in Saskatchewan, where blood-borne and sexually transmitted infections continue to spread at alarming rates. (Source: CBC | Health)
Source: CBC | Health - March 26, 2021 Category: Consumer Health News Tags: News/Canada/Saskatchewan Source Type: news

Ukrainian Traffickers Sentenced for Counterfeit Cancer and Hepatitis Drugs
FDA OCI, Maksym Nienadov, Healthy Nation, Volodymyr Nikolaienko, Ukraine, counterfeit drug, smuggling, misbranded medicine, Keytruda, Abraxane, Epclusa, cancer, hepatitis C, oncology drug, undercover purchase, custody, prescription drugs, (Source: Office of Criminal Investigations (OCI) Press Releases)
Source: Office of Criminal Investigations (OCI) Press Releases - March 25, 2021 Category: Medical Law Authors: DOJ Source Type: news

Pfizer is now testing a COVID-19 pill
The treatment is a potent protease inhibitor, the same kind of technology used to treat HIV and hepatitis C. (Source: Reuters: Health)
Source: Reuters: Health - March 24, 2021 Category: Consumer Health News Source Type: news

End Vaccine Apartheid Before Millions More Die
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Mar 23 2021 (IPS) At least 85 poor countries will not have significant access to coronavirus vaccines before 2023. Unfortunately, a year’s delay will cause an estimated 2.5 million avoidable deaths in low and lower-middle income countries. As the World Health Organization (WHO) Director-General has put it, the world is at the brink of a catastrophic moral failure. Anis Chowdhury Vaccine apartheid The EU, US, UK, Switzerland, Canada and their allies continue to block the developing country proposal to temporarily suspend the World Trade Organization (W...
Source: IPS Inter Press Service - Health - March 23, 2021 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Development & Aid Economy & Trade Featured Global Headlines Health Human Rights Humanitarian Emergencies TerraViva United Nations Source Type: news

Neutrons reveal unpredicted binding between SARS-CoV-2, hepatitis C antiviral drug
(DOE/Oak Ridge National Laboratory) Researchers at the Oak Ridge National Laboratory used neutron scattering to investigate the interactions between telaprevir, a drug used to treat hepatitis C viral infection, and the SARS-CoV-2 main protease, the enzyme responsible for enabling the virus to reproduce. Unforeseen changes in the electric charges were discovered in the drug binding site of the protease enzyme that were not predicted by prevailing computer simulations. The research provides key insights for advancing drug design and drug repurposing efforts to treat COVID-19. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 23, 2021 Category: International Medicine & Public Health Source Type: news

Roche awarded WHO prequalification for the HIV and HCV tests on the cobas 6800/8800 Systems
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the cobas ® HIV-1 and cobas® HCV Tests for use on the cobas® 6800/8800 Systems have been awarded World Health Organization (WHO) prequalification. WHO prequalification helps regulators and procurers in low and middle-income countries to identify products that meet high quality standards and are safe and su itable for their intended use. This is of benefit to healthcare professionals and patients, for whom quality assured IVDs are essential for effective diagnosis and monitoring of therapeutic efficiency.  Increased access to dia...
Source: Roche Investor Update - March 11, 2021 Category: Pharmaceuticals Source Type: news

Roche awarded WHO prequalification for the HIV and HCV tests on the cobas 6800/8800 Systems
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the cobas ® HIV-1 and cobas® HCV Tests for use on the cobas® 6800/8800 Systems have been awarded World Health Organization (WHO) prequalification. WHO prequalification helps regulators and procurers in low and middle-income countries to identify products that meet high quality standards and are safe and su itable for their intended use. This is of benefit to healthcare professionals and patients, for whom quality assured IVDs are essential for effective diagnosis and monitoring of therapeutic efficiency.  Increased access to dia...
Source: Roche Media News - March 11, 2021 Category: Pharmaceuticals Source Type: news

ICYMI: WSJ showcases breakthrough science of COVID-19 vaccines and implications for future medicines
Building on deep scientific knowledge gained from decades of experience with viruses such as MERS, SARS, influenza, HIV and Hepatitis C, biopharmaceutical companies have madeunprecedented progress in advancing treatments and vaccines to help fight COVID-19. At this time, three vaccines and several treatments have received emergency use authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) with one treatment receiving FDA approval. Additional candidates under investigation have also shown promise. (Source: The Catalyst)
Source: The Catalyst - March 8, 2021 Category: Pharmaceuticals Tags: Vaccines Coronavirus Source Type: news

La FDA advierte del riesgo de sufrir da ños hepáticos graves con los tratamientos de Viekira Pak y Technivie contra la hepatitis C
[10/22/2015] La Administraci ón de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) está advirtiendo que los tratamientos de Viekira Pak y Technivie contra la hepatitis C pueden causar daños hepáticos graves, sobre todo en pacientes con una enfermedad del hígado subyacente en etapa avanzada. En consecuencia, estamos exigiéndole al fabricante que añada nueva información sobre este riesgo de seguridad a las etiquetas de información farmacológica. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 26, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Liver Cancer Profile Differs in Black Patients With Hep C
THURSDAY, Feb. 25, 2021 -- Black patients with hepatitis C virus (HCV) infection develop hepatocellular carcinoma (HCC) at an earlier disease stage and have better liver function at the time of diagnosis, according to a study published online Feb.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 25, 2021 Category: Pharmaceuticals Source Type: news

Why Is Liver Cancer More Lethal for Black Patients?
THURSDAY, Feb 26, 2021 -- Black people with hepatitis C develop liver cancer sooner than people in other racial groups and the cancer is often more aggressive, but current screening guidelines may not be broad enough to catch these cases early,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 25, 2021 Category: General Medicine Source Type: news

Hepatitis C and HIV Combined Screening in Primary Care Hepatitis C and HIV Combined Screening in Primary Care
This study evaluated the effectiveness of a combined screening program for HCV and HIV, which included a risk-assessment questionnaire and rapid tests for point-of-care diagnosis.Journal of Viral Hepatitis (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - February 25, 2021 Category: Infectious Diseases Tags: Gastroenterology Journal Article Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Severas reacciones cut áneas después de tratamiento combinado con los medicamentos Incivek (telaprevir), peginterferón alfa y ribavirina para la hepatitis C
El 19 de diciembre del 2012, La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) recibió informes sobre severas reacciones de la piel, algunas de ellas fatales, en pacientes que toman el medicamento Incivek (telaprevir) para la hepatitis C en combinación con los fármacos peginterferón alfa y ri bavirina (tratamiento combinado con Incivek). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 19, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Association of Hepatitis C Infection and Risk of Kidney Cancer Association of Hepatitis C Infection and Risk of Kidney Cancer
Do patients with hepatitis C have a significantly higher risk of developing kidney cancer?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 11, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Characteristics of SARS-CoV-2 Infection in Persons With HCV Characteristics of SARS-CoV-2 Infection in Persons With HCV
How prevalent is SARS-CoV-2 infection among persons with hepatitis C? Does stage of liver fibrosis impact infection rates?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 11, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

HCV Declines Level Off in HIV+ Men Who Have Sex With Men HCV Declines Level Off in HIV+ Men Who Have Sex With Men
The incidence of hepatitis C virus infection among HIV-positive men who have sex with men in the Netherlands fell once direct-acting antivirals became universally available in 2015, new findings show.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 11, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie
[10-22-2015] The U.S. Food and Drug Administration (FDA) is warning that hepatitis C treatments Viekira Pak and Technivie can cause severe liver injury mostly in patients with underlying advanced liver disease. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 7, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Broadening participation in clinical trials: A win for all
The objective is to engage in rea l-world, evidence-based research and bring trials to the local community, where a significant proportion of cancer care is rendered,” he adds.   To help, Cardinal Health ’s real-world evidence and insights teams analyze the real-world data collected from the sites, which can be compared to results from clinical trials to demonstrate the real-world value of therapies.   By bringing these studies to the community, many of the usual challenges are overcome, adds Gajra. These include trial site location (typically academic institutions) and the distances that ...
Source: EyeForPharma - January 6, 2021 Category: Pharmaceuticals Authors: Joseph Constance Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Informaci & oacute;n actualizada sobre la interacci & oacute;n entre el medicamento Victrelis (boceprevir) y ciertos medicamentos reforzados inhibidores de la proteasa del VIH
El 26 de abril del 2012, la Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) informó al público que, en estos momentos, no se recomienda tomar conjuntamente Victrelis (boceprevir), un inhibidor de la proteasa del virus de la hepatitis C (VHC) junto con ciertos inhibidores de la proteasa del virus de la inmunodeficiencia humana VIH reforzados con ritonavir, por la posibilidad de reducir la eficacia de los medicamentos, lo que puede desencadenar el aumento del VHC o VIH en la sangre (carga viral). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 6, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Nobel Prize reflects perseverance in scientific research
(Mary Ann Liebert, Inc./Genetic Engineering News) New Rochelle, NY, December 21, 2020--The 2020 Nobel Prize in Physiology or Medicine went to three researchers for their discovery of hepatitis C virus (HCV). The undying perseverance that it took to find and cure this elusive virus (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 21, 2020 Category: Cancer & Oncology Source Type: news

Kidney Transplant Outcomes Similar With Hep C+ Donors
FRIDAY, Dec. 18, 2020 -- Recipients of kidneys from donors infected with hepatitis C virus (HCV) have similar kidney allograft function and probability of rejection in the first year after transplantation as those who receive kidneys from donors... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 18, 2020 Category: Pharmaceuticals Source Type: news

One-Year Transplant Outcomes Similar With Kidneys From HCV+, HCV- Donors One-Year Transplant Outcomes Similar With Kidneys From HCV+, HCV- Donors
Outcomes for renal transplants from hepatitis C virus (HCV)-infected donors to HCV-negative recipients are similar to those for HCV-negative patients who receive kidneys from donors without HCV, according to a one-year follow-up study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 16, 2020 Category: Surgery Tags: Nephrology News Source Type: news

New viral detection technique uses smartphone camera to diagnose various infections
(American Association for the Advancement of Science) Scientists have developed a novel smartphone-based technique to diagnose viral infections that uses a deep learning algorithm to identify viruses in metal nanoparticle-labeled samples, enabling rapid virus detection without the need for skilled laboratory workers and expensive equipment. The system correctly identified clinically relevant concentrations of Zika, hepatitis B (HBV), or hepatitis C (HCV) in 134 patient samples with 98.97% sensitivity. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 16, 2020 Category: Infectious Diseases Source Type: news

One-year kidney allograft outcomes do not differ by hepatitis C status of donor
(National Kidney Foundation) Study published in AJKD shows that kidney allograft outcomes one year post-transplantation in hepatitis C virus (HCV)-negative recipients do not differ by the HCV status of the donor. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 14, 2020 Category: Infectious Diseases Source Type: news

Nobel Laureates on their Hunt for the Cure Nobel Laureates on their Hunt for the Cure
The 2020 Nobel Prize in Medicine is awarded to three scientists who discovered hepatitis C, an RNA virus that was curbed by common-sense public health measures before new antivirals could save lives.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 9, 2020 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

Cannabis Use and Diabetes Risk in Chronic HCV Infection Cannabis Use and Diabetes Risk in Chronic HCV Infection
This study suggests a potential protective effect of cannabis on the risk of diabetes in patients with chronic hepatitis C. What might be the mechanism behind this beneficial effect?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 9, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Hep C Testing, Identification Plummet During COVID-19
TUESDAY, Dec. 8, 2020 -- The COVID-19 systematic emergency response has led to a decrease in hepatitis C virus (HCV) testing and identification, according to a study published online Nov. 22 in the Journal of Primary Care& Community... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2020 Category: Pharmaceuticals Source Type: news

Violence and hepatitis C transmission in prison-a modified social ecological model - Sazzad HMS, McCredie L, Treloar C, Lloyd AR, Lafferty L.
BACKGROUND: Transmission of hepatitis C virus (HCV) among the prisoner population is most frequently associated with sharing of non-sterile injecting equipment. Other blood-to-blood contacts such as tattooing and physical violence are also common in the... (Source: SafetyLit)
Source: SafetyLit - December 5, 2020 Category: International Medicine & Public Health Tags: Violence and Weapons Issues Source Type: news

NIDCR's Winter 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Winter 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Welcomes New Director Rena D’Souza Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health s...
Source: NIDCR Science News - December 4, 2020 Category: Dentistry Source Type: news

COVID-19 pandemic responsible for decrease in hepatitis C testing
(Boston Medical Center) New research from Boston Medical Center finds that the COVID-19 emergency systemic changes made to decrease in-person visits during the pandemic have led to a decrease in hospital-wide Hepatitis C (HCV) testing by 50 percent, and a reduction in new HCV diagnoses by more than 60 percent. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 4, 2020 Category: International Medicine & Public Health Source Type: news

Patients Cured of HCV Still at High Liver Cancer Risk Patients Cured of HCV Still at High Liver Cancer Risk
The burden of hepatocellular carcinoma (HCC) appears likely to move from patients who currently have hepatitis C virus (HCV) infection to those who have previously been cured, a new modeling study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Many Infants With Hep C-Positive Moms Not Screened for HCV
WEDNESDAY, Nov. 25, 2020 -- Less than one-third of infants born to mothers with hepatitis C virus infection (HCV+) receive appropriate HCV follow-up testing, according to a study presented at The Liver Meeting, the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 25, 2020 Category: Pharmaceuticals Source Type: news

Health and care heroes honoured in parliamentary awards
Doctors and nurses working to combat Hepatitis C in the homeless during the pandemic, the team behind the UK ’s first virtual reality lung rehabilitation programme launched this year and the research team working on the COVID-19 vaccine have all been recognised in the regional round of the NHS parliamentary awards. (Source: NHS Networks)
Source: NHS Networks - November 24, 2020 Category: UK Health Source Type: news

Opt-Out Policy Increased HIV/HCV Testing Opt-Out Policy Increased HIV/HCV Testing
Bundled opt-out HIV/hepatitis C virus (HCV) testing increased the percentage of syringe service program (SSP) clients who received HIV and HCV rapid tests at enrollment into the program.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 19, 2020 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news

Vanquishing Hepatitis C: A Remarkable Success Story Vanquishing Hepatitis C: A Remarkable Success Story
A look back at one of the singular achievements in medical research of the past 25 years, and what improvements are still to come.Medscape Gastroenterology (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - November 17, 2020 Category: Transplant Surgery Tags: Gastroenterology Commentary Source Type: news

X-ray study explores potential of hepatitis C drugs to treat COVID-19
(DOE/Oak Ridge National Laboratory) Researchers at the Department of Energy's Oak Ridge National Laboratory investigated the binding properties of several hepatitis C drugs to determine how well they inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce. Inhibiting, or blocking, the protease from functioning is vital to stopping the virus from spreading in patients with COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - November 16, 2020 Category: Infectious Diseases Source Type: news

HCV Care Can Learn a Thing or Two From the HIV Experience HCV Care Can Learn a Thing or Two From the HIV Experience
Patients with hepatitis C virus and HIV share some of the same treatment challenges, suggesting similar care models can be used for these conditions to improve rates of treatment adherence and success.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 15, 2020 Category: Gastroenterology Tags: Nursing News Source Type: news

Researchers discover enzyme suppressing immune response to viral infections
(University of Missouri-Columbia) Viruses such as HIV, hepatitis B and hepatitis C evade or disrupt the immune system to create persistent infections. These viruses remain a serious health threat, but researchers from the University of Missouri School of Medicine have discovered how an enzyme that regulates several cellular processes might be a key target to preventing viruses from disarming the human immune response. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 10, 2020 Category: Cancer & Oncology Source Type: news

New video: See how strong IP protections lead to stronger treatments for patients
Intellectual property (IP) protections, including patents, are the foundation for biopharmaceutical innovation and the development of new treatments, cures and vaccines for patients. A strong IP system is what has allowed the American biopharmaceutical industry to become the world leader in new medicine development and has allowed us to make unprecedented strides in treating everything from acute leukemia to hepatitis C and more. (Source: The Catalyst)
Source: The Catalyst - November 9, 2020 Category: Pharmaceuticals Authors: Tom Wilbur Tags: Intellectual Property IP Explained Source Type: news

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients
Basel, 22 October 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea ’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in a Phase 2 clinical trial for hospitalised patients with moderate COVID-19. A Phase 3 clinical trial, expected to start in Q1 2021, will explore the potential use in patients outside of the hospital setting. In...
Source: Roche Media News - October 22, 2020 Category: Pharmaceuticals Source Type: news

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients
Basel, 22 October 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea ’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in a Phase 2 clinical trial for hospitalised patients with moderate COVID-19. A Phase 3 clinical trial, expected to start in Q1 2021, will explore the potential use in patients outside of the hospital setting. In...
Source: Roche Investor Update - October 22, 2020 Category: Pharmaceuticals Source Type: news

A promising discovery could lead to better treatment for Hepatitis C
(Institut national de la recherche scientifique - INRS) Virologists at Institut national de la recherche scientifique (INRS) have identified a critical role played by a cellular protein in the progression of Hepatitis C virus infection, paving the way for more effective treatment. No vaccine currently exists for Hepatitis C virus infection, which affects more than 130 million people worldwide and nearly 250,000 Canadians. Antivirals exist but are expensive and not readily available in developing countries, where the disease is most prevalent. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - October 22, 2020 Category: Infectious Diseases Source Type: news

Virologists: What Do They Do?
Virologists are highly skilled medical experts who manage the diagnosis, treatment, and prevention of infectious diseases such as hepatitis C, Ebola, and now COVID-19. Learn more about them. (Source: WebMD Health)
Source: WebMD Health - October 20, 2020 Category: Consumer Health News Source Type: news